Adjuvant ICIs Plus Targeted Therapies Reduce HCC Recurrence after Hepatectomy in Patients with High Risk of Recurrence

Background: The high recurrence rate of hepatocellular carcinoma (HCC) after hepatectomy usually results in poor prognosis. To the best of our knowledge, no study has reported the efficacy of immune checkpoint inhibitors (ICIs) plus targeted therapies on preventing HCC recurrence after hepatectomy....

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Jianming, Jiang, Shijie, Chen, Yewu, Zhang, Jian, Deng, Yinan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9955678/
https://www.ncbi.nlm.nih.gov/pubmed/36826093
http://dx.doi.org/10.3390/curroncol30020132

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9955678/
https://www.ncbi.nlm.nih.gov/pubmed/36826093
http://dx.doi.org/10.3390/curroncol30020132

Ejemplares similares